SCHEMBL25262002

SCHEMBL25262002

COc1cc(-c2nccs2)c(-c2ccc3c(N)cnnc3c2)cc1B(O)OC=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 12/20 0.36
SCN9A Q15858 2/20 0.34
SMPD3 Q9NY59 1/20 0.32
DHFR P00374 2/20 0.31
JAK2 O60674 1/20 0.31
LCK P06239 1/20 0.31
CSF1R P07333 1/20 0.31
LYN P07948 1/20 0.31
RET P07949 1/20 0.31
IGF1R P08069 1/20 0.31
PDGFRB P09619 1/20 0.31
FGR P09769 1/20 0.31
KIT P10721 1/20 0.31
FGFR1 P11362 1/20 0.31
SRC P12931 1/20 0.31
PDGFRA P16234 1/20 0.31
FGFR2 P21802 1/20 0.31
FGFR4 P22455 1/20 0.31
FGFR3 P22607 1/20 0.31
KIF5B P33176 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25300128 0.91 PDE10A (0.38) PDE10ASCN9ASMPD3DHFRJAK2
SCHEMBL25262027 0.90 LRRK2 (0.31) LRRK2
SCHEMBL25840830 0.90 PDE10A (0.41) PDE10ASCN9ASMPD3DHFRJAK2
SCHEMBL26067398 0.88 PDE10A (0.39) PDE10ASCN9ASMPD3DHFRJAK2
SCHEMBL25303150 0.87 PDE10A (0.36) PDE10A
SCHEMBL25303435 0.87 PDE10A (0.36) PDE10AGABRA1GABRG2GABRB3GABRA3
SCHEMBL25303841 0.87 PDE10A (0.36) PDE10A
SCHEMBL25299474 0.84 CHEK2 (0.32) LRRK2
SCHEMBL25260407 0.84 PDE10A (0.36) PDE10A
SCHEMBL25259570 0.82 PDE10A (0.36) PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
WO-2023137166-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. (US) 2023-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PDE10A 1950/4885SCN9A 3732/4885SMPD3 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.